NCT04324164 Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
| NCT ID | NCT04324164 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hunan Province Tumor Hospital |
| Condition | Non-small Cell Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 800 participants |
| Start Date | 2020-03-24 |
| Primary Completion | 2025-12-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 800 participants in total. It began in 2020-03-24 with a primary completion date of 2025-12-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
Eligibility Criteria
Inclusion Criteria: * 18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology * Uncommon EGFR Mutant Advanced NSCLC Exclusion Criteria: * Patients with contraindication of chemotherapy * Pregnant or breast feeding women
Contact & Investigator
Yongchang Zhang, MD
PRINCIPAL INVESTIGATOR
Hunan Cancer Hospital
Frequently Asked Questions
Who can join the NCT04324164 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non-small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04324164 currently recruiting?
Yes, NCT04324164 is actively recruiting participants. Contact the research team at zhangyongchang@csu.edu.cn for enrollment information.
Where is the NCT04324164 trial being conducted?
This trial is being conducted at Changsha, China.
Who is sponsoring the NCT04324164 clinical trial?
NCT04324164 is sponsored by Hunan Province Tumor Hospital. The principal investigator is Yongchang Zhang, MD at Hunan Cancer Hospital. The trial plans to enroll 800 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.